Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs

The emergence of avian influenza A(H7N9) virus in poultry causing zoonotic human infections was reported on March 31, 2013. Development of A(H7N9) candidate vaccine viruses (CVV) for pandemic preparedness purposes was initiated without delay. Candidate vaccine viruses were derived by reverse genetics using the internal genes of A/Puerto/Rico/8/34 (PR8). The resulting A(H7N9) CVVs needed improvement because they had titers and antigen yields that were suboptimal for vaccine manufacturing in eggs, especially in a pandemic situation.

[1]  J. Pirkle,et al.  Quantification of viral proteins of the avian H7 subtype of influenza virus: an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemic. , 2014, Analytical chemistry.

[2]  K. Subbarao,et al.  Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets , 2014, Journal of Virology.

[3]  I. Wilson,et al.  Preferential Recognition of Avian-Like Receptors in Human Influenza A H7N9 Viruses , 2013, Science.

[4]  Jessie C. Chang,et al.  Structural Analysis of the Hemagglutinin from the Recent 2013 H7N9 Influenza Virus , 2013, Journal of Virology.

[5]  S. Hensley,et al.  Compensatory Hemagglutinin Mutations Alter Antigenic Properties of Influenza Viruses , 2013, Journal of Virology.

[6]  D. Spiro,et al.  Molecular Signature of High Yield (Growth) Influenza A Virus Reassortants Prepared as Candidate Vaccine Seeds , 2013, PloS one.

[7]  Yu Wang,et al.  Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses , 2013, The Lancet.

[8]  Sebastian Maurer-Stroh,et al.  Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model , 2013, PLoS pathogens.

[9]  Z. Ye,et al.  Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains. , 2012, Vaccine.

[10]  R. Webster,et al.  Receptor-Binding Profiles of H7 Subtype Influenza Viruses in Different Host Species , 2012, Journal of Virology.

[11]  K. Stöhr,et al.  Influenza virus surveillance, vaccine strain selection, and manufacture. , 2012, Methods in molecular biology.

[12]  A. Klimov,et al.  Influenza virus titration, antigenic characterization, and serological methods for antibody detection. , 2012, Methods in molecular biology.

[13]  D. Bucher,et al.  Gene Constellation of Influenza A Virus Reassortants with High Growth Phenotype Prepared as Seed Candidates for Vaccine Production , 2011, PloS one.

[14]  T. Wolff,et al.  Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content. , 2011, Vaccine.

[15]  C. Davis,et al.  The development of vaccine viruses against pandemic A(H1N1) influenza. , 2011, Vaccine.

[16]  Weizhong Yang,et al.  Development of a new candidate H5N1 avian influenza virus for pre‐pandemic vaccine production , 2009, Influenza and other respiratory viruses.

[17]  Y. Kawaoka,et al.  Identification of amino acid residues of influenza A virus H3 HA contributing to the recognition of molecular species of sialic acid , 2009, FEBS letters.

[18]  Rahul Raman,et al.  Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift , 2009, Science.

[19]  R. Donis,et al.  Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. , 2009, Current topics in microbiology and immunology.

[20]  O. Engelhardt,et al.  Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). , 2008, Vaccine.

[21]  N. Cox,et al.  Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. , 2008, Vaccine.

[22]  N. Cox,et al.  Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. , 2008, Vaccine.

[23]  Rino Rappuoli,et al.  Vaccine manufacturing: challenges and solutions , 2006, Nature Biotechnology.

[24]  L. Brown,et al.  An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin , 2005, Archives of Virology.

[25]  R. Webster,et al.  Eight-plasmid system for rapid generation of influenza virus vaccines. , 2002, Vaccine.

[26]  H. Klenk,et al.  Interdependence of Hemagglutinin Glycosylation and Neuraminidase as Regulators of Influenza Virus Growth: a Study by Reverse Genetics , 2000, Journal of Virology.

[27]  L. Mitnaul,et al.  Balanced Hemagglutinin and Neuraminidase Activities Are Critical for Efficient Replication of Influenza A Virus , 2000, Journal of Virology.

[28]  C. Bender,et al.  Differences in the biological phenotype of low-yielding (L) and high-yielding (H) variants of swine influenza virus A/NJ/11/76 are associated with their different receptor-binding activity. , 1998, Virology.

[29]  R. Webster,et al.  Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. , 1994, Virology.

[30]  C. Naeve,et al.  Single-amino-acid substitution in an antigenic site of influenza virus hemagglutinin can alter the specificity of binding to cell membrane-associated gangliosides , 1989, Journal of virology.

[31]  G. Schild,et al.  Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. , 1971, The Journal of infectious diseases.